ALKERMES | ALKS - Pre Tax Profit



ALKERMES reported $104.84M in Pre-Tax Profit for its fiscal quarter ending in June of 2025.


Pre Tax Profit Change Date
AbbVie USD 1.66B 3.15B Mar/2025
Acadia Pharmaceuticals USD 40.21M 12.43M Jun/2025
ALKERMES USD 104.84M 79.35M Jun/2025
Amgen USD 1.57B 405M Jun/2025
Biogen USD 744M 432.8M Jun/2025
BioMarin Pharmaceutical USD 297.87M 59.78M Jun/2025
Bristol-Myers Squibb USD 1.77B 1.2B Jun/2025
Eli Lilly USD 6.78B 3.32B Jun/2025
Gilead Sciences USD 2.43B 780M Jun/2025
Ionis Pharmaceuticals USD 124M 271M Jun/2025
J&J USD 13.63B 8.21B Mar/2025
Merck USD 6.77B 864M Jun/2025
Neurocrine Biosciences USD 159.5M 144.8M Jun/2025
Otsuka Holdings JPY 112.98B 391M Jun/2025
Pfizer USD 3.04B 259M Jun/2025
Regeneron Pharmaceuticals USD 1.52B 613.7M Jun/2025
Vertex Pharmaceuticals USD 1.28B 552.6M Jun/2025